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Abstract
Background: Adult-onset Still’s disease (AOSD) is a rare inflammatory condition characterized by fever, rash, and
arthritis. Because of its rarity, clinical trials are inherently small and often uncontrolled. Our objective was to develop
recommendations for the use of interleukin (IL)-1 inhibitors in the management of patients with AOSD, based on
the best evidence and expert opinion.
Methods: A panel of 10 experts (9 rheumatologists and 1 pediatrician) was established. The first step was
dedicated to a comprehensive literature review and development of statements. Two separate literature searches
were performed on the MEDLINE (Pubmed), EMBASE, and BIOSIS databases through April 2018 to identify (1)
differences and similarities between AOSD and pediatric Still’s disease (systemic juvenile idiopathic arthritis [SJIA])
and (2) the efficacy and safety of IL-1 inhibitors in AOSD treatment. In the second step, the statements were
submitted in a Delphi process to a panel of 67 rheumatologists. Consensus threshold was set at 66%: positive, >
66% of voters selected scores 3 to 5; negative, > 66% of voters selected scores 1 or 2. In the third step, the voting
results were analyzed, and the statements were finalized.
Results: Eleven statements were developed. Forty-six of 67 rheumatologists (72%) participated in the Delphi
process. A positive consensus was reached after the first round of voting and was full (> 95%) on the majority of
statements. A large consensus was achieved in considering AOSD and SJIA as the same disease. The use of anti-IL-1
therapies in refractory patients was considered quite safe and effective both as the first and as a subsequent line of
biologic treatment, especially in systemic patients. Because of the lack of head-to-head comparisons, a different
profile of efficacy among IL-1 inhibitors could not be established. There was a large consensus that failure of the
first IL-1 inhibitor does not preclude response to another one. The lack of studies comparing early versus late
treatment did not allow to draw conclusions; however, data from SJIA suggest a better response in early treatment.
Conclusions: The Delphi method was used to develop recommendations that we hope will help clinicians in the
management of patients with AOSD refractory to conventional therapies.
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Introduction
Still’s disease is a rare systemic inflammatory disorder
that can develop both in adults and children and is char-
acterized by a wide spectrum of manifestations, includ-
ing a typical triad of symptoms: daily spiking fever,
polyarthritis, and a characteristic salmon-colored skin
rash [1]. Still’s disease was first defined in children,
whereas the adult form was described in 1971, following
the identification of a clinical condition in adults with
clinical and laboratory features similar to that observed
in children [1, 2]. The childhood form of the disease is
currently termed systemic juvenile idiopathic arthritis
(SJIA), while the adult form is known as adult-onset
Still’s disease (AOSD) [1]. Despite attempts to identify
serological biomarkers, there is currently no universally
standardized biomarker for AOSD [3]. The diagnosis of
AOSD is still challenging and frequently based on the
exclusion of other conditions, with consequent diagnos-
tic delays [4, 5]. Although many experts view SJIA and
AOSD as the same disease, the true relationship between
the two conditions has long been a matter of debate [1].
Based on the presence of predominant “systemic” or
“chronic articular” manifestations, two different subtypes
of AOSD have been proposed [6]. These two subtypes
are characterized by distinct serological profiles, with
evidence of a major pro-inflammatory state in the sys-
temic form compared to the articular form [6–10].
The pathophysiology of Still’s disease is largely un-
known, but recent advances have identified interleukin
(IL)-1β as a crucial inflammatory mediator [6, 11]. Both
SJIA and AOSD have been shown to respond dramatic-
ally to the IL-1β blockade [12]. Currently available IL-1
inhibitors include anakinra, canakinumab, and rilona-
cept. Anakinra, a human recombinant IL-1 receptor an-
tagonist, is approved in the European Union (EU) for
Still’s disease (SJIA and AOSD) with active systemic fea-
tures of moderate to high disease activity, or after the
failure of conventional treatments [non-steroidal anti-
inflammatory drugs (NSAIDs) or glucocorticoids] [13].
Canakinumab, a human monoclonal anti-human IL-1β
antibody, is approved in the EU for the treatment of ac-
tive AOSD and SJIA, following an inadequate response
to NSAIDs and systemic corticosteroids [14]; according
to the US FDA label, canakinumab is indicated for active
SJIA [15]. Rilonacept, an IL-1 trap fusion protein, is cur-
rently not licensed for use in Still’s disease either in Eur-
ope or the USA [16, 17].
To date, there are no guidelines for the management
of Still’s disease, and the treatment of this condition is
mostly empirical and challenging for many clinicians.
Because of the rarity of the disease, very few clinical
studies are available. Specifically, there is only one ran-
domized controlled trial (RCT) on the use of anakinra in
patients with AOSD [18], and data supporting the
efficacy/safety of canakinumab are only available from
two RCTs performed in patients with SJIA [19]. Based
on the similarities with SJIA, the European Medicines
Agency (EMA) has now approved the use of canakinu-
mab in patients with AOSD [20]. To address the lack of
evidence-based guidance on the management of AOSD,
a panel of ten Italian physicians with expertise in the
management of Still’s disease convened a meeting in
January 2018 with the goal of addressing unresolved is-
sues and reaching consensus about the management of
patients with AOSD using IL-1 inhibitors. The issues ad-
dressed by the panel were mainly related to the relation-
ship between SJIA and AOSD, the efficacy and safety of
IL-1β blockade in AOSD, the optimal timing for treat-
ment initiation, and the efficacy of these agents in the
articular versus the systemic form of AOSD. After a
comprehensive review of the literature, the panel used a
Delphi process to develop consensus statements on the
management of AOSD. This article presents the out-
comes of this process as a summary of the consensus
statements and supportive literature.
Methods
Design
A panel composed of 9 Italian rheumatologists and 1
pediatrician expert in pediatric rheumatology (scientific
board of the project) were chosen based on their clinical
experience and expertise in the treatment of Still’s dis-
ease (Table 1). Expertise to qualify for the scientific
board was defined as having treated more than 15 pa-
tients with AOSD in the previous 15 years and being an
author on at least 1 published article on AOSD. In
addition, the panel members were from diverse areas of
Italy in order to gain geographic representation from
across the country.
The scientific panel met in Milan on January 23, 2018,
to discuss the issues related to the treatment of AOSD
with anti-IL-1 inhibitors and to plan the development of
a series of expert opinion- and evidence-based state-
ments addressing these issues. During the first meeting,
a comprehensive search of the literature was planned to
gather the available evidence on the relationship be-
tween SJIA and AOSD and on IL-1β blockade in AOSD.
Because a limited number of publications were expected,
especially with regard to the efficacy/safety of anti-IL-1
agents in AOSD, the scientific board decided to base the
statements on a combination of available evidence and
consensus procedures, which had to be conducted
through a Delphi process. The Delphi technique is
widely used in medical research to generate consensus
on controversial or insufficiently documented issues
[21–25]. The degree of reliability of a given statement
depends on the percentage of consensus achieved
through voting by a panel of experts. For issues on
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which no consensus was reached, the voting process was
repeated after a plenary discussion among the experts or
the review of supporting literature.
Consensus development process
The consensus development process was undertaken be-
tween April 2018 and October 2018 and consisted of
three steps: (i) comprehensive literature review and writ-
ing of statements; (ii) evaluation of statements by a panel
of rheumatologists, who were asked to express their
agreement or disagreement on each statement; and (iii)
assessment of voting results and finalization of the
statements.
The first step involved two meetings. The first meeting
was held in Milan on April 3, 2018, and was attended by
the scientific board and by 4 additional rheumatologists
(AB, SC, MM, TS), who were responsible for the search
and selection of the literature (bibliographic board). The
aim of this meeting was to design the strategy of the lit-
erature search. During the second meeting, held on Sep-
tember 10, 2018, the bibliographic board presented the
results of the literature search. Based on the results of
the literature review, 11 statements were drafted. The
level of evidence (range 1–5) and the grade of recom-
mendation (range A–D) were assigned to each statement
according to the Oxford Centre for Evidence-Based
Medicine [26].
In the second step of the consensus process (the
Delphi portion), the statements were circulated elec-
tronically to a panel of 67 rheumatologists from 31
Italian rheumatology centers; since AOSD is a rare
disease requiring specialist management, these rheu-
matologists were all members of the Working Group
of Systemic Autoinflammatory Diseases of the Società
Italiana Reumatologia (SIR; Italian Society of Rheuma-
tology) and were from all areas of Italy (Table 1).
The rheumatologists were invited to express their
agreement or disagreement about each statement,
using a 5-point Likert scale (1 = maximal disagree-
ment, 2 = disagreement, 3 = agreement, 4 = strong
agreement, 5 = absolute [total] agreement). The con-
sensus threshold was set at 66%. A positive consensus
was considered to be reached when > 66% of voters
selected the scores 3 to 5 and negative consensus to
be reached when > 66% of voters selected the scores
1 or 2. If consensus was not reached, the statements
were submitted to the second round of discussion
and review.
At the third and final step of the consensus process,
the scientific board and the bibliographic board ana-
lyzed the voting results and finalized the statements
during a final meeting held in Milan on October 16,
2018.
Literature search strategy
Two separate literature searches were undertaken. These
literature searches were performed on three databases
(MEDLINE via Pubmed, Embase, and BIOSIS Previews).
No start date for the literature search was defined, but
the end date was April 20, 2018.
First, a systematic literature review was performed
to identify reports describing the similarities and
differences of SJIA and AOSD. A search strategy was
developed using Mesh (or Emtree) terms and free-
text words identifying AOSD and SJIA
(Additional file 1: Table S1). The reviewers selected
the literature pertaining to the similarities and differ-
ences of AOSD and SJIA, by limiting the analysis to
studies or case series addressing clinical features, out-
comes, laboratory parameters, response to treatment,
genetic profile, and classification criteria.
A second systematic literature review was performed
to identify articles describing the efficacy and safety of
IL-1β blockade in AOSD. Four specific clinical questions
were considered relevant in relation to the treatment of
AOSD with IL-1 inhibitors: (1) efficacy and safety of IL-
1 inhibitors in general, (2) comparative efficacy and
safety of different IL-1 inhibitors, (3) comparison of early
versus late treatment with IL-1 inhibitors, and (4) rela-
tive efficacy of IL-1 inhibitors in patients with a systemic
versus chronic articular pattern of AOSD. Each clinical
question was phrased according to the Patient, Interven-
tion, Control, Outcomes (PICO) strategy for study selec-
tion. The main database searches were complemented
by a manual search of proceedings from the European
League Against Rheumatism (EULAR) and American
Table 1 Membership of the scientific board and Delphi respondents
Participating experts Number Specialty, n (%) Hospital-based, n (%)1 University-based, n (%)1 Geographical origin, n (%)
Scientific board 10 Rheumatology, 9 (90)
Pediatrics, 1 (10)
6 (60) 8 (80) Northern Italy, 7 (70)
Central Italy, 2 (20)
Southern Italy, 1 (10)
Bibliographic board 4 Rheumatology (100) 2 (50) 3 (75) Northern Italy, 3 (75)
Central Italy, 1 (25)
Delphi respondents 49 Rheumatology (100) 22 (45) 43 (88) Northern Italy, 20 (41)
Central Italy, 18 (37)
Southern Italy, 11 (22)
1Percentages do not add to 100 because some experts are both hospital- and university-based
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College of Rheumatology (ACR) congresses of the
previous 2 years (2016 and 2017) and also by scrutin-
izing the reference lists of included articles. A search
strategy was developed using Mesh (or Emtree) terms
and free-text words identifying AOSD, along with po-
tential terms for anti-IL-1 agents (Additional file 1:
Table S2). The potential terms for the anti-IL-1
agents included brand names and generic names for
the individual IL-1 inhibitors, as well as generic terms
for interleukin-1 and “anti,” “inhibit,” “block,” or “an-
tagonist.” The study selection and data extraction
were performed by two independent reviewers. For
the evaluation of efficacy outcomes, only controlled
clinical trials, cohort studies, or case series were




Relationship between AOSD and SJIA
The literature search identified 332 publications
(Additional file 1: Table S1). After the selection of
studies corresponding to inclusion criteria, 30 publica-
tions comparing AOSD and SJIA were identified.
These covered similarities and differences in clinical
features, outcomes, laboratory parameters, and re-
sponse to treatment [4, 27–47], genetic profile [48–
50], and classification criteria for AOSD and SJIA
[51–56]. Two relevant reviews on AOSD were also
identified [1, 6].
Efficacy and safety of IL-1 inhibition in AOSD
The search of the literature about IL-1 inhibition in
AOSD (Additional file 1: Table S2) identified 358 publi-
cations; among them, 27 publications other than case re-
ports were selected as relevant to the clinical questions
being investigated (Table 2).
These articles included 1 RCT [18, 33, 61], 1 post
hoc analysis of pooled study results [31], 1 prospect-
ive open-label trial [54], 5 nationwide surveys [60, 66,
71, 73, 74], 17 retrospective observational studies or
case series [6, 8, 57–59, 62–64, 67, 68, 70, 72, 76,
78], 1 meta-analysis [69], and 1 comprehensive review
[77]. A total of 60 case reports, mostly related to the
use of anakinra were also identified; 7 case reports
described the use of canakinumab in AOSD [79–85],
and 3 case reports documented the use of rilonacept
in AOSD [83, 86, 87]; the complete list of case re-
ports can be viewed in Additional file 1: Table S3
[27, 59, 79–134].
Delphi process and consensus development
Based on the review of the literature and on personal
clinical experience, the scientific board developed 11
statements concerning the relationship between AOSD
and SJIA and the role of IL-1 inhibition in the treatment
of AOSD. The statements (English translation) are
shown in Table 3 along with the results of the Delphi
voting.
A total of 49 rheumatologists out of the 67 invited by
the scientific board participated in the Delphi process
(72% participation rate). The threshold for positive con-
sensus (> 66% agreement) was reached on each state-
ment during the first round of voting, and no additional
Delphi rounds were required. Consensus exceeded 95%
for the majority of statements.
Relationship between AOSD and SJIA
Statement 1.1. Adult Onset Still’s Disease (AOSD)
and Systemic Juvenile Idiopathic Arthritis (SJIA) show
substantial similarities in terms of clinical
manifestations [3b], laboratory features [3b], response
to treatment [3b] and, possibly, genetic background
[4]. [Grade C]
Statement 1.2. Adult Onset Still’s Disease (AOSD)
and Systemic Juvenile Idiopathic Arthritis (SJIA) may
be considered the same disease. Differences in the
rate of clinical manifestations could be related to the
age of onset [5]. [Grade D]
As shown in Table 4, despite a few differences, there
is a substantial overlap between AOSD and SJIA in
clinical characteristics, laboratory parameters, outcomes,
and response to treatment. Among the eight studies
comparing clinical features (Table 4), the presence of a
higher incidence of sore throat in adults seems to be
the only relevant clinical difference [32, 36, 38, 44]. A
single small report suggests a higher rate of amyloidosis
in AOSD, potentially in line with the older age of
AOSD patients [32]. One study reported a higher fre-
quency of polyarthritis in AOSD [4], yet most studies
indicate similar articular involvement [32, 33, 36, 38,
41, 44] with evidence of progressive and erosive arthritis
in both adults and children [4, 32, 36]. Although chil-
dren are more likely to develop an intermittent articular
pattern, arthritis seems to occur with similar frequency
in SJIA and AOSD [4, 38]. However, worse outcomes
have been described in patients with pediatric onset,
presumably related to the longer disease duration [36].
Concerning the overall course of the disease, there also
seems to be no difference between SJIA and AOSD [4,
32]. In most studies, response to treatment is also simi-
lar [4, 32, 33, 37, 38, 44]; better articular outcomes in
patients with AOSD than in those with SJIA have been
reported in only one study [36]. Taken together, the
clinical evidence supports the statement that AOSD and
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SJIA may be regarded as the same disease, and the few
differences in the frequency of signs and symptoms
could be related to the age of the affected individual at
the time of their first encounter with potential disease-
triggering factors [1].
The similarity of clinical features is not the sole evi-
dence supporting the notion that AOSD and SJIA
may be the same disease. The genetic profiles show
similarities in the upregulation of genes involved in
the IL-1 signaling pathway (e.g., IL-1β, IL-1 receptor
accessory protein, IL-1RN, and IL-1 receptors 1 and 2)
and downregulation of genes regulating proliferation and
immune function (e.g., AKTCD24, CD28CD3D,
CD6CD69, CDC25B, and CDC7) [49]. There may be dif-
ferences in the HLA genotype between SJIA and AOSD.
In particular, compared to the healthy population, an as-
sociation with the HLA-DR4 gene has been found only in
SJIA [48], whereas the HLA-B14 and HLA-DR7 genes
were shown to be associated with AOSD [48].
To date, the diagnosis of SJIA is based on the
International League of Associations for Rheumatol-
ogy (ILAR) criteria [135, 136], whereas AOSD is diag-
nosed according to the Yamaguchi criteria [137].
However, there is increasing evidence that either set
of criteria can be applied to both groups of patients.
This evidence lends further support to the possibility
that AOSD and SJIA represent a continuum of the
same condition. Yang and colleagues [53] found good
concordance between ILAR and Yamaguchi criteria in
patients with AOSD; moreover, fulfilling ILAR criteria
in patients with AOSD seems to be predictive for a
worse outcome. On the contrary, SJIA patients meet
Yamaguchi criteria more commonly than ILAR cri-
teria [52, 54]. A possible explanation is that although
arthritis is a key criterion for the diagnosis of SJIA
(ILAR criteria), this feature is often absent, particu-
larly at disease onset [52]. On the other hand, accord-
ing to the Yamaguchi criteria, arthritis is not a
mandatory criterion for AOSD [137]. Notably, a revi-
sion of the ILAR classification criteria for SJIA has
been recently proposed, which makes them more
similar to the Yamaguchi criteria [138]. The overall
goal of this revision is to identify more homogeneous
clinical subgroups of JIA patients and to distinguish
the forms of chronic arthritis seen only in children
from those that also occur in adult patients. In the
newly proposed classification criteria, SJIA is consid-
ered equivalent to AOSD, and an adaptation of the
Yamaguchi criteria has been chosen to classify SJIA. Ac-
cording to the proposal, arthritis is no longer required to
classify SJIA, thereby recognizing that as in AOSD, pa-
tients with SJIA may have systemic features without arth-
ritis. These preliminary criteria will be formally validated
through a multinational prospective data collection [138].
IL-1 inhibition in AOSD
Statement 2.1. There is evidence that IL-1 inhibition
represents an effective therapeutic approach in AOSD
refractory to conventional treatment and/or other bio-
logics [2a]. [Grade B]
Statement 2.2. In AOSD, treatment with IL-1 Inhibi-
tors is effective on different clinical and laboratory pa-
rameters and displays a significant steroid-sparing
effect in most patients [2a]. Therapeutic response is
rapid and sustained over time. [Grade B]
Statement 2.3. IL-1 inhibitors are effective in the
treatment of AOSD-related Macrophage Activation
Syndrome (MAS) [4], although cases of MAS occur-
ring during treatment with these drugs are reported
[2b]. [Grade C]
Statement 2.4. IL-1 Inhibitors have an overall satisfac-
tory safety profile in AOSD [2b]. Among adverse
events, infections have been reported [2b]. Treatment
with anakinra has been associated with frequent
injection-site reactions [2b] and occasionally severe
cases of hepatotoxicity, reversible after treatment
withdrawal [5]. [Grade C]
Based on our review of the literature, therapies targeting
IL-1 (anakinra, canakinumab, and rilonacept) are signifi-
cantly effective in patients with AOSD refractory to con-
ventional treatment (Table 5) [6, 18, 33, 35, 60–68, 70–73,
75, 76, 78]. Among the 20 studies reported in Table 5, the
effectiveness of anti-IL-1 therapies in AOSD ranged from
50 to 100% (median 83.3%); the rate of remission ranged
from 22.2 to 100% (median 70%) and the treatment failure
rate from 0 to 50% (median 16.7%). Data on remission
must be interpreted with caution since this disease state
was not defined in some studies [6, 62, 64, 68, 75] and was
defined variably in others [18, 33, 60, 63, 66, 70, 73, 76].
One of the lowest rates of remission (22.2%) was reported
in a study in which remission was defined purely on the
basis of articular manifestations (i.e., 100% improvement
in American College of Rheumatology response criteria)
[33], while the highest rates (80–100%) were reported in
studies that did not provide a definition of remission [6,
62, 64, 68]. In studies requiring complete recovery of sys-
temic and articular symptoms, as well as normalization of
inflammatory biomarkers, the rate of remission varied
between 14.2 and 70% [18, 66, 70, 73, 76]. The most
stringent definition of remission was provided by
Cavalli and colleagues [70], who required the absence
of systemic and articular manifestations, the
normalization of acute phase reactants (C-reactive pro-
tein and erythrocyte sedimentation rate), and a
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reduction in corticosteroid dosage (≥ 50% for at least 2
months). Using this definition, 70% of patients receiv-
ing anakinra achieved remission [70].
Our data are in agreement with a previous review of
the literature performed by Junge and colleagues in 2017
[77]; this review reported that anti-IL-1 agents were
Table 6 Safety of anti-IL agents (anakinra, canakinumab, and rilonacept) in refractory patients with AOSD: data from retrospective
observational studies, nationwide survey, and clinical trials
Study Design Study drug Adverse event, no. of patients
Injection site reactions (ISR)
Naumann et al. [62] RO Anakinra 2/8 (25%)
Laskari et al. [63] RO Anakinra 5/25 (20%)
Gerfaud-Valentine et al. [68] RO Anakinra “Some”/6
Cavalli et al. [70] RO Anakinra 2/20 (10%)
Colafrancesco et al. [76] RO Anakinra 28/140 (20%)
Giampietro et al. [66] Nationwide survey Anakinra “Some”/28
Ortiz-Sanjuan et al. [71] Nationwide survey Anakinra 6/41 (14.6%)
Nordstrom et al. [18] Clinical trial (RCT) Anakinra 8/12 (66.6%)
Diffuse cutaneous reactions (rash/urticaria/eczema)
Laskari et al. [63] RO Anakinra 3/25 (12%)
Quartuccio et al. [65] RO Anakinra 3/10 (30%)
Toz et al. (abstract) [75] RO Anakinra 1/7 (14.2%)
Colafrancesco et al. [76] RO Anakinra 12/140 (8.5%)
Lequerre et al. [60] Nationwide survey Anakinra 2/15 (13.3%)
Ortiz-Sanjuan et al. [71] Nationwide survey Anakinra 2/41 (4.8%)
Feist et al. [33] Clinical trial (post hoc analysis) Canakinumab 13/31 (41.9%)
Infections (mild and severe)
Laskari et al. [63] RO Anakinra 6/25 mild (24%); 1/25 severe (4%)
Cavalli et al. [70] RO Anakinra 2/20 mild (10%)
Colafrancesco et al. [76] RO Anakinra 4/140 mild (2.8%); 2/140 severe (1.4%)
Lequerre et al. [60] Nationwide survey Anakinra 4/15 mild (26.6%); 1/15 severe (6.6%)
Ortiz-Sanjuan et al. [71] Nationwide survey Anakinra 3/41 mild (7.3%); 2/41 severe (4.8%)
Rossi-Semerano et al. [73] Nationwide survey Anakinra 2/35 severe (5.7%)
Henderson et al. [61] Clinical trial (POL dose escalation) Rilonacept 2/5 severe (40%)
Feist et al. [33] Clinical trial (post hoc analysis) Canakinumab 21/31 mild (67.7%); 2/31 severe (6.4%)
Other adverse events
Quartuccio et al. [65] RO Anakinra 2/10 (20%) (thrombocytopenia)
Colafrancesco et al. [76] RO Anakinra 2/140 (1.4%) (thrombocytopenia)
1/140 (0.7%) (leukopenia) 1/140
(0.7%) (lymphoproliferative disorders)
Lequerre et al. [60] Nationwide survey Anakinra 1/15 (6.6%) (Hip osteonecrosis)
Ortiz-Sanjuan et al. [71] Nationwide survey Anakinra 3/41 (7.3%) (leukopenia) 1/41 (2.4%) (myopathy)
Feist et al. [33] Clinical trial (post hoc analysis) Canakinumab 18/31 (58%) (GI disorders) 10/31 (32.2%) (respiratory)
Macrophage activation syndrome
Colafrancesco et al. [76] RO Anakinra 6/140 (4.2%)
Colafrancesco et al. [76] RO Canakinumab 1/4 (25%)
Rossi-Semerano et al. [73] Nationwide survey Anakinra 1/35 (2.8%)
Henderson et al. [61] Clinical trial (POL dose escalation) Rilonacept 1/5 (20%)
Feist et al. [33] Clinical trial (post hoc analysis) Canakinumab 3/31 (9.6%)
AOSD adult-onset Still’s disease, POL prospective open-label, RCT randomized controlled trial, RO retrospective observational
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associated with high rates of full remission (55–75%)
and of full or partial remission (91–100%) [77]. The con-
sistent response to all three anti-IL-1 agents, regardless
of the different mechanisms by which they block IL-1β,
is a further demonstration of the involvement of IL-1β
in the pathogenesis of AOSD.
According to our review of the literature, in most pa-
tients with AOSD, it is possible to significantly reduce
the dosage of concomitant corticosteroids during treat-
ment with anti-IL-1 therapy [18, 60, 62, 63, 66, 67, 70,
71, 76]. Moreover, corticosteroid withdrawal was
achieved in 17 to 48% of patients [18, 60, 63, 70, 76].
This result is consistent with a pooled analysis of pub-
lished data on IL-1 inhibitors in AOSD, which reported
an overall rate of corticosteroid discontinuation of 36.9%
(95% CI 24.0–52.0%) [69].
Data on the efficacy of anti-IL1 agents in the treatment
of arthritis in patients with AOSD are still controversial.
During treatment with anakinra, a significant reduction in
the proportion of AOSD patients with arthritis has been
reported [60, 63, 71, 76]. A reduction in DAS28 score after
85 days of therapy with canakinumab has also been dem-
onstrated [33]. However, despite such improvements, in
some cases, a complete resolution of arthritis could not be
achieved [71, 76]. In contrast, systemic manifestations of
AOSD, such as fever and rash, showed rapid and sustained
disappearance during IL-1 inhibitor therapy [6, 18, 33, 60,
62–68, 70, 71, 73, 76, 78].
Based on our analysis, the most frequently reported
adverse events during IL-1 inhibitor treatment are injec-
tion site reactions (ISRs), which develop in 10 to 66.6%
of patients receiving anakinra (Table 6) [18, 62, 63, 66,
70, 71, 76, 97]. The largest retrospective observational
study reported a 20% incidence of ISRs in patients
treated with anakinra [76].
In addition to ISRs, diffuse cutaneous reactions, such as
skin rash, urticaria and, in some cases, eczema, have been
reported during treatment with anakinra or canakinumab
(Table 6) [33, 60, 63, 65, 71, 75, 76]. Other common ad-
verse events include infections and gastrointestinal disor-
ders [33, 60, 61, 63, 70, 71, 73, 76]. The rate of severe
infections is quite low, with a reported frequency between
1.4 and 6.6% in patients treated with anakinra and 6.4% in
patients treated with canakinumab [33, 60, 61, 63, 70, 71,
73, 76]. In patients receiving anakinra or canakinumab,
mild infections, most commonly respiratory tract infec-
tions, are generally more frequent than severe infections
[33, 60, 61, 63, 70, 71, 73, 76]. In terms of the risk of infec-
tion, treatment with anti-IL-1 agents seems to have an ac-
ceptable safety profile.
Other less frequent adverse events are reported in
Table 6 [33, 60, 65, 71, 76]. Although rare, severe ad-
verse events, mainly represented by major infections,
may occur. Specifically, mycobacterial infections, viral
infections (cytomegalovirus, varicella zoster), and pneu-
monia have been reported [33, 61, 71, 73, 76]. Anakinra
has also been associated with occasional cases of severe
hepatotoxicity that is reversible after treatment with-
drawal [89, 112, 139].
Instances of MAS have been reported during treat-
ment with anti-IL-1 agents (anakinra, canakinumab, and
rilonacept) (Table 6) [33, 61, 73, 76, 79]. However, be-
cause MAS is a frequent complication of AOSD, it is im-
possible to attribute these events with certainty to the
treatment.
Despite limited data, anakinra appears relatively safe
during pregnancy [117, 140]. Smith and Chambers
[140] reported pregnancy outcomes in five women
(three with AOSD and two adults with pediatric-onset
SJIA) who received anakinra during the third trimes-
ter of pregnancy. All five women delivered live infants
at term; two pregnancies had complications (oligohy-
dramnios in both, accompanied by pregnancy-induced
hypertension in one) [140]. One infant had a low
birth weight (2419 g), but none had major long-term
complications or malformations [140]. Similarly,
Fischer-Betz and colleagues reported successful preg-
nancy outcomes in two women treated with anakinra
(one who started treatment during pregnancy and the
other who received anakinra throughout pregnancy)
[117, 140]. Neither woman chose to breastfeed during
anakinra therapy.
Evidence on pregnancies in patients exposed to IL-1
inhibitors has substantially increased with the publica-
tion of a large case series (43 pregnancies) by Youngstein
and colleagues [141]. This article provided the first re-
ports of pregnancy outcome in women treated with
canakinumab, as well as reporting on outcomes in
women treated with anakinra. The data show that the 2
agents are safe, and most infants were born healthy. One
woman with an active disease during 2 pregnancies ex-
perienced 2 miscarriages, the first during treatment with
anakinra and the second under canakinumab. One case
of unilateral renal agenesis was also reported in an infant
exposed to anakinra during pregnancy. In this study,
data regarding the outcome of paternal IL-1 inhibitor in-
take were also available. Specifically, all the infants born
from fathers treated with IL-1 inhibitors at conception
(6 with anakinra and 5 with canakinumab) were healthy
and did not have congenital or developmental abnormal-
ities [141].
Taken together, the available data indicate that IL-1
inhibitor therapy is a valid treatment in patients with
AOSD who fail to improve with conventional therapies.
Response to IL-1 inhibitors is rapid and sustained, and
this form of treatment allows patients to reduce their de-
pendence on corticosteroids. The overall safety profile of
IL-1 inhibitors is also generally favorable.
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Efficacy and safety of the various IL-1 inhibitors in AOSD
Statement 3.1. A different profile of efficacy among
IL-1 inhibitors cannot be established, because head-
to-head comparisons are lacking and available data re-
garding the use of canakinumab and rilonacept are al-
most exclusively after anakinra failure [5]. [Grade D]
Statement 3.2. Considering available data on efficacy,
failure of the first IL-1 inhibitor does not preclude the
achievement of a therapeutic response with another
IL-1 inhibitor [5]. [Grade D]
There are no head-to-head studies comparing the avail-
able anti-IL1 agents in patients with AOSD. Because of its
original indication in rheumatoid arthritis, anakinra has
been on the market for longer than the other com-
pounds and therefore has been the most extensively
investigated in patients with AOSD. Canakinumab
and rilonacept are generally used in patients who
have had an inadequate response to anakinra, so any
indirect comparison between the agents is affected by
selection bias and should be interpreted with caution.
In the review of treatment with IL-1 inhibitors by
Junge and colleagues, efficacy outcomes were mea-
sured in the same ways across different reports [77].
According to this review, anakinra is characterized by
rapid and often sustained efficacy, leading to a re-
duced need for corticosteroids. Systemic symptoms
resolve quickly, but joint symptoms may be more per-
sistent [77]. Anakinra has a short half-life, so the effi-
cacy is relatively short-lived and daily administration
is required [13]. Besides ISRs that occur with daily in-
jections, other adverse events associated with anakinra
include infections, elevated liver enzymes, mild
leukopenia, and myopathy [13].
The review by Junge and colleagues noted that canakinu-
mab was effective in difficult-to-treat AOSD patients and
was well tolerated [77]. To date, the published reports on
the use of canakinumab in AOSD describe its use in pa-
tients previously treated with other anti-IL1 agents, mainly
anakinra. These reports demonstrate that canakinumab is
effective even in these difficult-to-treat patients who are
likely to have more severe disease. Based on our systematic
review of the literature and on the most recent review by
Galozzi and colleagues [20], there are only 24 published
cases of patients with AOSD who were treated with canaki-
numab. These reports show efficacy in reducing both sys-
temic and articular manifestations, while reducing the need
for corticosteroids. These preliminary findings of efficacy
are being confirmed in a multicenter, randomized placebo-
controlled trial with canakinumab in AOSD patients with
active joint involvement (NCT02204293) that is currently
underway in Germany [142].
Early versus late treatment of AOSD with IL-1 inhibitors
Statement 4.1. There are no available studies
comparing the efficacy of treatment with IL-1 inhibi-
tors in early versus late stages of AOSD. Data from
SJIA suggest that early treatment with IL-1 inhibitors
is associated with a better therapeutic response [5].
[Grade D]
Statement 4.2. Indirect data show that IL-1 inhibitors
can be effective in AOSD, both in first and subsequent
lines of biologic treatment [2b]. [Grade B]
Early use (soon after disease onset) of IL-1 inhibi-
tors in AOSD has not been explored yet. Direct com-
parisons of early versus late initiation of treatment
with IL-1 inhibitors are also not available. The evi-
dence from studies in SJIA suggests that early treat-
ment with anti-IL-1 therapy is associated with a
better response and that IL-1 inhibitors may be a
valuable option in the first-line disease setting [77,
143–145]. Indirect evidence from the available reports
suggests that IL-1β blockade is effective as the first-
line intervention, as well as in later lines of treatment
(up to the sixth line of treatment with biologics) [8,
57–60, 62, 64, 68, 70].
Efficacy of treatment therapy with anti-IL-1 agents on
systemic and joint disease
Statement 5.1. Some data suggest that IL-1 inhibitors
may be more effective on systemic rather than chronic
articular manifestations of AOSD [2b]. [Grade C]
To date, there is no study specifically aimed at
comparing the effects of anti-IL-1 therapy on systemic
versus articular manifestations of AOSD. However, in-
direct evidence suggests that anti-IL-1 agents may be
more effective at relieving systemic disease [6, 8, 60,
62, 66, 68, 70, 77]. Specifically, in the study by
Giampietro et al., a complete response to anakinra
was reported in 46.7% of patients with systemic dis-
ease (n = 15) compared to 38.4% of patients with the
chronic articular pattern (n = 13) [66]. A much higher dif-
ference in terms of response was reported by Cavalli et al.
who identified a complete rate of response in 91.6% of pa-
tients with systemic disease (n = 12) compared to 37.5% of
patients with articular disease (n = 8) [70]. These find-
ings are consistent with the pattern of response re-
ported in children with SJIA, in whom IL-1 inhibitors
appear to be more effective in improving non-
articular signs and symptoms (such as fever, rash, and
inflammatory markers) than on the arthritic features
of the disease [60, 146–148].
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Discussion
A large body of evidence supports the similarity between
AOSD and SJIA. Furthermore, both conditions respond
to agents that inhibit IL-1β by distinct mechanisms,
which confirm the pivotal role of IL-1β in the pathogen-
esis of these conditions.
The likely differences in pharmacokinetics and
pharmacogenetics between AOSD and SJIA do not allow
us to extrapolate information on the effectiveness and
safety profile of IL-1 inhibitors from SJIA to AOSD. This
is the main reason why we decided to perform this sys-
tematic review of the literature specifically on AOSD.
The aim of this study was to clearly collect and
summarize all of the available evidence supporting the
use of IL-1 inhibitors specifically in patients with AOSD,
for which information is scarce compared with SJIA.
While studies on the pharmacokinetics of anakinra [149]
or canakinumab [150] in patients with SJIA are available,
there are still no comparable data in patients with
AOSD. Nonetheless, there should be obvious differences
in IL-1 inhibitor pharmacokinetics related to age, body
weight, and genetic profile. This crucial point underlines
the need to summarize current evidence on AOSD in
order to provide guidelines for clinicians prescribing
these drugs in this rare condition.
Most of the data on the efficacy and safety of IL-1
blockers in AOSD describe the use of anakinra, and the
evidence from RCTs is limited to one small study inves-
tigating this medication [18]. Nevertheless, the available
data consistently demonstrate a clinical benefit with
these agents, with only a few patients being non-
responsive to IL-1 blockers. Some reports describe pa-
tients who experience rapid and marked improvement in
the signs and symptoms of AOSD after the first injection
[6, 59, 62, 99, 100]. In patients who respond to IL-1 in-
hibitor therapy, complete remission can be maintained
for prolonged periods (≥ 12months) [59, 80, 87, 96, 100,
103]. Data from case reports provide anecdotal support
for the use of a different IL-1 inhibitor in patients who
do not respond or only partially respond to the first
agent [80–83, 85, 87].
We used a modified Delphi process to develop the re-
ported consensus statements. This technique has the ad-
vantage of being able to systematically synthesize the
knowledge and opinions of a large group of individuals
with diverse expertise and from different geographic lo-
cations, thereby limiting the potential for a small group
of experts from one area to dominate [25] (Appendix).
By collecting responses anonymously, the Delphi method
is able to counteract the effect of any psychological pres-
sures that can influence opinions in a small-group dis-
cussion environment, such as ideological or status
differences or a tendency by some members to dominate
others. When conducted well, the Delphi method can
provide valid guidance to clinical practice in situations
where there is limited empirical evidence [25]. Our
process was robust, the participation rate by Italian phy-
sicians with expertise in auto-inflammatory conditions
was high, and our panel included a nationally represen-
tative sample of experts from most geographic regions
in Italy (Table 1). Moreover, there was a high rate of
consensus on most statements. These results reflect the
favorable outcomes of clinical reports on the use of IL-1
inhibitors in patients with AOSD, as well as the physi-
cians’ own positive clinical experience with these agents.
Our study is not without limitations. We set a rela-
tively low threshold for consensus (> 66%) [151], al-
though all of the statements generated consensus of ≥
88%, so the chosen threshold does not affect the validity
of the consensus. Delphi-based research is a method for
making the best use of available information [24]. How-
ever, it should not replace properly conducted scientific
research, and it is important to emphasize that the
current recommendations should be validated in well-
designed, prospective clinical studies. Indeed, it should
be taken into account that data coming from our sys-
tematic review of the literature are mainly based on
retrospective study cohorts. Data on anakinra include
one RCT [18], while data on canakinumab come only
from small case series and a single pooled analysis of
study data [33, 76, 77]. In addition, the majority of data
on canakinumab come from AOSD patients previously
treated with anakinra, with a consequent selection bias
for patients with the most aggressive and difficult to
treat forms of AOSD [76, 77]. Thus, more data on this
therapy are needed in patients with AOSD, particularly
on its use as the first-line IL-1 inhibitor. Of note, at the
time when we performed the systematic review of the
literature, there were no studies evaluating the efficacy
of canakinumab in AOSD as the first-line therapy. A
study by Cavalli and colleagues, which evaluated the ef-
fectiveness of canakinumab as the first-line biologic
agent in patients with AOSD and reported excellent
clinical response rates, has since been published [152].
Although the evidence of the overall efficacy of anti-
IL1 agents in patients with AOSD, especially in those
with the systemic form of the disease, is quite convin-
cing, the effectiveness of these medications on articular
involvement should be further explored. For this reason,
the results of the ongoing RCT with canakinumab
(NCT02204293) in patients with AOSD and active joint
involvement are eagerly awaited.
Data on anakinra in patients with AOSD are mainly
based on retrospective observational studies. Following
the only existing RCT of anakinra in patients with
AOSD, the results of which were published in 2012 [18];
a new RCT on anakinra in AOSD is currently ongoing
(NCT03265132). This trial aims to evaluate anakinra
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efficacy in newly diagnosed SJIA and AOSD patients and
to investigate its safety, pharmacokinetics (PK), and im-
munogenicity. The data from this trial, which is enrol-
ling patients with a disease duration of less than 6
months, will provide key information regarding the effi-
cacy of this treatment, especially in the early disease
stages.
Conclusions
Although adequately powered RCTs on the use of IL-1 in-
hibitors in AOSD are lacking, the literature is consistent
in demonstrating a beneficial effect of these agents, with a
high proportion of patients achieving rapid and sustained
remission of systemic symptoms and normalization of in-
flammatory markers. Given the absence of a strong evi-
dence base for the use of IL-1 inhibitors in AOSD, a
robust and careful Delphi process was undertaken to de-
velop consensus recommendations on the use of these
agents, which we hope will assist physicians in the rational
prescribing of these agents for patients affected by this
condition.
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